{"protocolSection": {"identificationModule": {"nctId": "NCT01485614", "orgStudyIdInfo": {"id": "0431-083"}, "secondaryIdInfos": [{"id": "2011-002528-42", "type": "EUDRACT_NUMBER"}, {"id": "MK-0431-083", "type": "OTHER", "domain": "Merck Protocol Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)", "officialTitle": "A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2022-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-02-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-10-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-10-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-12-01", "studyFirstSubmitQcDate": "2011-12-01", "studyFirstPostDateStruct": {"date": "2011-12-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-10-05", "resultsFirstSubmitQcDate": "2020-11-18", "resultsFirstPostDateStruct": {"date": "2020-12-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-09-09", "lastUpdatePostDateStruct": {"date": "2022-09-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of the study is to assess the safety of the addition of sitagliptin, and its effect on hemoglobin A1c (A1C) in pediatric participants 10-17 years of age with type 2 diabetes mellitus (T2DM) with inadequate glycemic control. The primary hypothesis for this study is that sitagliptin reduces A1C more than placebo after 20 weeks of treatment.", "detailedDescription": "This trial is of approximately 56 weeks in duration, including a screening period of up to 1 week, a 1-week single-blind placebo run-in period, a 20-week placebo-controlled, double blind treatment period \\[Phase A\\] and a 34-week double-blind active controlled treatment period \\[Phase B\\] during which participants randomized to the placebo arm who have not initiated glycemic rescue therapy with metformin during Phase A will receive metformin (in a blinded manner). A telephone contact will be performed 14 days after the last dose of study medication to assess for any serious adverse events (SAEs).\n\nParticipants enrolled in the metformin and placebo/sitagliptin arms prior to implementation of Protocol Amendment 05 completed the study on their original treatment assignments.\n\nEUPASS4468 is a follow-up, non-interventional, observational assessment of safety of participants who participated in the MK-0431-083 study for up to 5 years."}, "conditionsModule": {"conditions": ["Diabetes Mellitus", "Type 2 Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 200, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.", "interventionNames": ["Drug: Sitagliptin", "Drug: Placebo to metformin", "Drug: Glycemic Rescue 1", "Biological: Glycemic Rescue 2"]}, {"label": "Placebo/Metformin", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.", "interventionNames": ["Drug: Metformin", "Drug: Placebo to sitagliptin", "Drug: Placebo to metformin", "Drug: Glycemic Rescue 1", "Biological: Glycemic Rescue 2"]}, {"label": "Metformin", "type": "ACTIVE_COMPARATOR", "description": "Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.", "interventionNames": ["Drug: Metformin"]}, {"label": "Placebo/Sitagliptin", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.", "interventionNames": ["Drug: Sitagliptin", "Drug: Placebo to sitagliptin", "Drug: Placebo to metformin"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin 100 mg tablet administered orally once daily", "armGroupLabels": ["Placebo/Sitagliptin", "Sitagliptin"], "otherNames": ["Januvia\u00ae, Tesavel\u00ae, Xelevia\u00ae, Ristaben\u00ae, Glactiv\u00ae"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily", "armGroupLabels": ["Metformin", "Placebo/Metformin"], "otherNames": ["Glucophage\u00ae, Metgluco\u00ae, Glycoran\u00ae"]}, {"type": "DRUG", "name": "Placebo to sitagliptin", "description": "Matching placebo to sitagliptin 100 mg tablet administered orally once daily", "armGroupLabels": ["Placebo/Metformin", "Placebo/Sitagliptin"]}, {"type": "DRUG", "name": "Placebo to metformin", "description": "Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily", "armGroupLabels": ["Placebo/Metformin", "Placebo/Sitagliptin", "Sitagliptin"]}, {"type": "DRUG", "name": "Glycemic Rescue 1", "description": "Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.", "armGroupLabels": ["Placebo/Metformin", "Sitagliptin"]}, {"type": "BIOLOGICAL", "name": "Glycemic Rescue 2", "description": "Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.", "armGroupLabels": ["Placebo/Metformin", "Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1C (A1C) at Week 20", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C.", "timeFrame": "Baseline and Week 20"}, {"measure": "Baseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm", "description": "A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C from a longitudinal data analysis (LDA) model. The placebo arm in this comparison is a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The Statistical Analysis Plan (SAP) did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "timeFrame": "Baseline and Week 20"}, {"measure": "Number of Participants Who Experienced \u22651 Adverse Event During Weeks 0-56", "description": "The number of participants experiencing \u22651 adverse event during Weeks 0-56 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "timeFrame": "Up to Week 56"}, {"measure": "Percentage of Participants Who Experienced \u22651 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)", "description": "The number of participants experiencing \u22651 adverse event during Weeks 0-56 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "timeFrame": "Up to Week 56"}, {"measure": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54", "description": "The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "timeFrame": "Up to Week 54"}, {"measure": "Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)", "description": "The percentage of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "timeFrame": "Up to Week 54"}], "secondaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 54", "description": "A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. This change from baseline reflects the Week 54 A1C minus the Week 0 A1C.", "timeFrame": "Baseline and Week 54"}, {"measure": "Percentage of Participants With A1C at Goal (<7.0%) at Week 20", "description": "The percentage of participants with A1C at goal (\\<7.0%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).", "timeFrame": "Week 20"}, {"measure": "Percentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))", "description": "The percentage of participants with A1C at goal (\\<7.0%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "timeFrame": "Week 20"}, {"measure": "Percentage of Participants With A1C at Goal (<6.5%) at Week 20", "description": "The percentage of participants with A1C at goal (\\<6.5%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).", "timeFrame": "Week 20"}, {"measure": "Percentage of Participants With A1C at Goal (<6.5%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))", "description": "The percentage of participants with A1C at goal (\\<6.5%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "timeFrame": "Week 20"}, {"measure": "Percentage of Participants With A1C at Goal (<7.0%) at Week 54", "description": "The percentage of participants with A1C at goal (\\<7.0%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).", "timeFrame": "Week 54"}, {"measure": "Percentage of Participants With A1C at Goal (<6.5%) at Week 54", "description": "The percentage of participants with A1C at goal (\\<6.5%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).", "timeFrame": "Week 54"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20", "description": "Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline.", "timeFrame": "Baseline and Week 20"}, {"measure": "Baseline Fasting Plasma Glucose (FPG) for the Placebo (Pooled) Arm", "description": "Blood glucose was measured on a fasting basis. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in FPG at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))", "description": "Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline and was estimated from a longitudinal data analysis model. The current outcome measure focused on results from participants randomized to sitagliptin or placebo. The Week 20 treatment comparison of Sitagliptin vs Placebo included all participants treated with Sitagliptin or Placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in FPG at Week 54", "description": "Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 54 minus FPG at baseline.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 20", "description": "PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour PMG minus the Week 0 2-hour PMG.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in 2-hour PMG at Week 54", "description": "PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour PMG minus the Week 0 2-hour PMG.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in 2-hour Incremental PMG at Week 20", "description": "2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in 2-Hour Incremental PMG at Week 54", "description": "2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Insulin at Week 20 for Participants Not on Background Insulin", "description": "This change from baseline reflects the Week 20 insulin minus the Week 0 insulin.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Insulin at Week 54 For Participants Not on Background Insulin", "description": "This change from baseline reflects the Week 54 insulin minus the Week 0 insulin.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Proinsulin at Week 20 For Participants Not on Background Insulin", "description": "This change from baseline reflects the Week 20 proinsulin minus the Week 0 proinsulin.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Proinsulin at Week 54 For Participants Not on Background Insulin", "description": "This change from baseline reflects the Week 54 proinsulin minus the Week 0 proinsulin.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Proinsulin/Insulin Ratio at Week 20 for Participants Not on Background Insulin", "description": "Change from baseline was the Week 20 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Proinsulin/Insulin Ratio at Week 54 For Participants Not on Background Insulin", "description": "The change from baseline was Week 54 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Homeostatic Model Assessment of \u03b2-cell Function (HOMA-\u03b2) at Week 20 For Participants Not on Background Insulin", "description": "HOMA-\u03b2 = 20 \u00d7 fasting insulin (in mcIU/mL) \u00f7 {\\[FPG (in mg/dL)/18\\] - 3.5}. The change from baseline was Week 20 HOMA-\u03b2 minus the Week 0 HOMA-\u03b2.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in HOMA-\u03b2 at Week 54 For Participants Not on Background Insulin", "description": "HOMA-\u03b2 = 20 \u00d7 fasting insulin (in mcIU/mL) \u00f7 {\\[FPG (in mg/dL)/18\\] - 3.5}. This change from baseline was Week 54 HOMA-\u03b2 minus the Week 0 HOMA-\u03b2.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 20 For Participants Not on Background Insulin", "description": "HOMA-IR = fasting insulin (in mcIU/mL) \u00d7 FPG (in mg/dL) / (22.5\u00d718). This change from baseline was Week 20 HOMA-IR minus the Week 0 HOMA-IR.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in HOMA-IR at Week 54 For Participants Not on Background Insulin", "description": "HOMA-IR = fasting insulin (in mcIU/mL) \u00d7 FPG (in mg/dL) / (22.5\u00d718). This change from baseline was Week 54 HOMA-IR minus the Week 0 HOMA-IR.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Glucose 3-Hour Total Area Under the Curve (AUC) at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Insulin 3-hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in C-peptide 3-Hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Insulin 3-Hour AUC/ Glucose 3-Hour AUC Ratio at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin total AUC/glucose total AUC ratio minus the Week 0 insulin total AUC/glucose total AUC ratio.", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Glucose Excursion 3-Hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Insulin Excursion 3-Hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in C-peptide Excursion 3-Hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Glucose 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Insulin 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in C-peptide 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Insulin 3-Hour AUC/Glucose 3-Hour AUC Ratio at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC/glucose 3-hour AUC ratio minus the Week 0 insulin 3-hour AUC/glucose 3-hour AUC ratio.", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Glucose Excursion 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Insulin Excursion 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in C-Peptide Excursion 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)"}, {"measure": "Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20", "description": "The percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.", "timeFrame": "Up to Week 20"}, {"measure": "Percentage of Participants Initiating Glycemic Rescue Therapy by Week 54", "description": "The percentage of participants who initiated glycemic rescue therapy prior to Week 54 was reported.", "timeFrame": "Up to Week 54"}, {"measure": "Change From Baseline in Body Mass Index (BMI) at Week 20", "description": "This change from baseline was Week 20 BMI minus the Week 0 BMI.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in BMI at Week 54", "description": "This change from baseline was Week 54 BMI minus the Week 0 BMI.", "timeFrame": "Baseline and Week 54"}, {"measure": "Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 20", "description": "The percent change from baseline in CD26 = (\\[CD26 value at Week 20\\] - \\[baseline CD26 value\\]) \u00f7 baseline CD26 value \u00d7 100.", "timeFrame": "Baseline and Week 20"}, {"measure": "Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 54", "description": "The percent change from baseline in CD26 = (\\[CD26 value at Week 54\\] - \\[baseline CD26 value\\]) \u00f7 baseline CD26 value \u00d7 100.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Calcitonin at Week 20 - Females", "description": "Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Calcitonin at Week 54 - Females", "description": "Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Calcitonin at Week 20 - Males", "description": "Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Calcitonin at Week 54 - Males", "description": "Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Bone Collagen [u-NTx]/Creatinine Ratio at Week 20 - Females", "description": "Urine N-terminal cross-linking telopeptide of bone collagen \\[u-NTx\\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline u-NTx/Creatinine Ratio at Week 20 - Males", "description": "Urine N-terminal cross-linking telopeptide of bone collagen \\[u-NTx\\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Females", "description": "Urine N-terminal cross-linking telopeptide of bone collagen \\[u-NTx\\]/creatinine ratio is a biochemical marker of bone turnover/resorption. Bone Collagen Equivalents", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Males", "description": "Urine N-terminal cross-linking telopeptide of bone collagen \\[u-NTx\\]/creatinine ratio is a biochemical marker of bone turnover/resorption. All participants in the Metformin arm were missing baseline or Week 54 measurements. BCE = Bone Collagen Equivalents", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Females", "description": "Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Females", "description": "Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Males", "description": "Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Males", "description": "Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.", "timeFrame": "Baseline and Week 54"}, {"measure": "Percent Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) at Week 20 - Females", "description": "IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\\[IGF-1 value at Week 20\\] - \\[baseline IGF-1 value\\]) \u00f7 \\[baseline IGF-1 value\\] \u00d7 100.", "timeFrame": "Baseline and Week 20"}, {"measure": "Percent Change From Baseline in IGF-1 at Week 54 - Females", "description": "IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\\[IGF-1 value at Week 54\\] - \\[baseline IGF-1 value\\]) \u00f7 \\[baseline IGF-1 value\\] \u00d7 100.", "timeFrame": "Baseline and Week 54"}, {"measure": "Percent Change From Baseline in IGF-1 at Week 20 - Males", "description": "IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\\[IGF-1 value at Week 20\\] - \\[baseline IGF-1 value\\]) \u00f7 \\[baseline IGF-1 value\\] \u00d7 100.", "timeFrame": "Baseline and Week 20"}, {"measure": "Percent Change From Baseline in IGF-1 at Week 54 - Males", "description": "IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\\[IGF-1 value at Week 54\\] - \\[baseline IGF-1 value\\]) \u00f7 \\[baseline IGF-1 value\\] \u00d7 100.", "timeFrame": "Baseline and Week 54"}, {"measure": "Percent Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) at Week 20 - Females", "description": "IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\\[IGF-BP3 value at Week 20\\] - \\[baseline IGF-BP3 value\\]) \u00f7 \\[baseline IGF-BP3 value\\] \u00d7 100.", "timeFrame": "Baseline and Week 20"}, {"measure": "Percent Change From Baseline in IGF-BP3 at Week 54 - Females", "description": "IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\\[IGF-BP3 value at Week 54\\] - \\[baseline IGF-BP3 value\\]) \u00f7 \\[baseline IGF-BP3 value\\] \u00d7 100.", "timeFrame": "Baseline and Week 54"}, {"measure": "Percent Change From Baseline in IGF-BP3 at Week 20 - Males", "description": "IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\\[IGF-BP3 value at Week 20\\] - \\[baseline IGF-BP3 value\\]) \u00f7 \\[baseline IGF-BP3 value\\] \u00d7 100.", "timeFrame": "Baseline and Week 20"}, {"measure": "Percent Change From Baseline in IGF-BP3 at Week 54 - Males", "description": "IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\\[IGF-BP3 value at Week 54\\] - \\[baseline IGF-BP3 value\\]) \u00f7 \\[baseline IGF-BP3 value\\] \u00d7 100.", "timeFrame": "Baseline and Week 54"}, {"measure": "Growth Velocity at Week 20 - Females", "description": "Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).", "timeFrame": "Week 20"}, {"measure": "Growth Velocity at Week 54 - Females", "description": "Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).", "timeFrame": "Week 54"}, {"measure": "Growth Velocity at Week 20 - Males", "description": "Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).", "timeFrame": "Week 20"}, {"measure": "Growth Velocity at Week 54 - Males", "description": "Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).", "timeFrame": "Week 54"}, {"measure": "Skeletal Maturation at Week 20 - Females", "description": "Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from an X-ray of left hand and wrist.", "timeFrame": "Week 20"}, {"measure": "Skeletal Maturation at Week 54 - Females", "description": "Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Placebo/Sitagliptin arm were missing baseline or Week 54 measurements.", "timeFrame": "Week 54"}, {"measure": "Skeletal Maturation at Week 20 - Males", "description": "Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist.", "timeFrame": "Week 20"}, {"measure": "Skeletal Maturation at Week 54 - Males", "description": "Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Metformin and Placebo/Sitagliptin arms were missing baseline or Week 54 measurements.", "timeFrame": "Week 54"}, {"measure": "Change From Baseline in Tanner Staging for Genitalia at Week 20 - Males", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 20 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Tanner Staging for Genitalia at Week 54 - Males", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 54 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia. All participants in the Metformin arm were missing baseline or Week 54 measurements.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Tanner Staging for Breasts at Week 20 - Females", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 20 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Tanner Staging for Breasts at Week 54 - Females", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 54 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Females", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Females", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Males", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Males", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.", "timeFrame": "Baseline and Week 54"}, {"measure": "Participants With Worsening in Dental Status at Week 20", "description": "Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 20 dental assessments versus baseline dental assessments.", "timeFrame": "Week 20"}, {"measure": "Participants With Worsening in Dental Status at Week 54", "description": "Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 54 dental assessments versus baseline dental assessments.", "timeFrame": "Week 54"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 Diabetes Mellitus (T2DM)\n* Has not received treatment with an antihyperglycemic agent (AHA) for \u226512 weeks prior to the Screening Visit/Visit 1, or is on a stable dose of insulin (without any other AHA) for at least 12 weeks prior to the Screening Visit/Visit 1. At screening, participants on insulin doses that are not stable can have their insulin doses adjusted and be eligible to participate after their dose remains stable for \u226512 weeks, if they meet all other eligibility criteria. In India, only participants on stable doses of insulin will be eligible.\n* An A1C of \u22656.5% and \u226410.0% (For participants on insulin: an A1C \u22657.0% and \u226410.0%).\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus, autoimmune diabetes mellitus or has a positive antibody screen for anti-GAD (Glutamic Acid Decarboxylase) or (Islet cell autoantigen) ICA-512.\n* Known monogenic diabetes, secondary diabetes, or a genetic syndrome or disorder known to affect glucose tolerance other than diabetes.\n* Symptomatic hyperglycemia and/or moderate to large ketonuria and/or positive test for ketonemia requiring immediate initiation of antihyperglycemic therapy.\n* Previously taken a DPP-4 (Dipeptidyl peptidase-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, or saxagliptin) or GLP-1 (Glucagon-like peptide-1) receptor agonist (such as exenatide or liraglutide).\n* Hypersensitivity or contraindication (according to the product circular in the country of the investigational site) to metformin.\n* Chronic treatment with a medication known to cause weight gain within 30 days of study start or weight loss or increased blood glucose within 8 weeks of study start or treated with an anti-psychotic within the past 12 weeks.\n* On a weight loss program and not in the maintenance phase or have undergone bariatric surgery within 12 months prior to study start.\n* On or likely to require treatment with \u226514 consecutive days or repeated courses of pharmacologic doses of corticosteroids.\n* Undergone a surgical procedure within the prior 4 weeks or has major surgery planned during the study.\n* History of congenital heart disease or cardiovascular disease other than hypertension.\n* Medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease.\n* Active nephropathy (i.e., nephrotic syndrome or glomerulonephritis).\n* Chronic myopathy, mitochondrial disorder, or a progressive neurological or neuromuscular disorder (e.g., polymyositis, or multiple sclerosis).\n* Human immunodeficiency virus (HIV) as assessed by medical history.\n* Clinically significant hematological disorder (such as aplastic anemia, thrombocytopenia, myeloproliferative or myelodysplastic syndrome).\n* Under treatment for hyperthyroidism.\n* Exhibits abnormal growth patterns or is being treated with growth hormone.\n* History of malignancy or clinically important hematologic disorder.\n* History of idiopathic acute pancreatitis or chronic pancreatitis.\n* Known history of recreational or illicit drug use, or of alcohol abuse or dependence (within the past year).\n* Donated blood products or has had phlebotomy of \\>10% of estimated total blood volume within 8 weeks of signing informed consent, or intends to donate blood products or receive blood products within the projected duration of the study.\n* Pregnant, has a positive urine pregnancy test at Screening Visit/Visit 1, is expecting to conceive within the projected duration of the study, or is breast-feeding.\n* Exclusionary laboratory values.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "10 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "34779087", "type": "DERIVED", "citation": "Shankar RR, Zeitler P, Deeb A, Jalaludin MY, Garcia R, Newfield RS, Samoilova Y, Rosario CA, Shehadeh N, Saha CK, Zhang Y, Zilli M, Scherer LW, Lam RLH, Golm GT, Engel SS, Kaufman KD. A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatr Diabetes. 2022 Mar;23(2):173-182. doi: 10.1111/pedi.13279. Epub 2021 Dec 22."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants in a one-week, run-in received sitagliptin placebo prior to morning meals and metformin placebo prior to morning and evening meals.\n\nParticipants enrolled in the metformin and placebo/sitagliptin arms prior to implementation of Protocol Amendment 05 completed the study on their original treatment assignments.", "recruitmentDetails": "The study recruited participants in clinics/clinical offices in 42 countries.", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "FG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "FG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "FG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "periods": [{"title": "Randomization", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "96"}, {"groupId": "FG001", "numSubjects": "90"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "95"}, {"groupId": "FG001", "numSubjects": "90"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Not Treated", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Weeks 0-20", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "95"}, {"groupId": "FG001", "numSubjects": "90"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "95"}, {"groupId": "FG001", "numSubjects": "90"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "86"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Parent/Guardian", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Weeks 20-54", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "86"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "74"}, {"groupId": "FG001", "numSubjects": "78"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Parent/Guardian", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The analysis population consisted of all randomized and treated participants.", "groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "BG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "BG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "BG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "199"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.3", "spread": "2.0"}, {"groupId": "BG001", "value": "13.7", "spread": "1.9"}, {"groupId": "BG002", "value": "13.3", "spread": "3.0"}, {"groupId": "BG003", "value": "15.0", "spread": "1.6"}, {"groupId": "BG004", "value": "14.0", "spread": "2.0"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "In utero", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Preterm newborn infants (gestational age < 37 wks)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Newborns (0-27 days)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Infants and toddlers (28 days-23 months)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Children (2-11 years)", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "25"}]}, {"title": "Adolescents (12-17 years)", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "174"}]}, {"title": "Adults (18-64 years)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "From 65-84 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "85 years and over", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "121"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "78"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "73"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "54"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "115"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "11"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "15"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "30"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "11"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "104"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "39"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Glycated Hemoglobin (A1C)", "description": "A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The analysis population includes all randomized participants who received \u22651 dose of study medication and had a baseline measurement of A1C.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.43", "spread": "1.02"}, {"groupId": "BG001", "value": "7.56", "spread": "1.08"}, {"groupId": "BG002", "value": "7.43", "spread": "1.07"}, {"groupId": "BG003", "value": "8.02", "spread": "0.75"}, {"groupId": "BG004", "value": "7.50", "spread": "1.04"}]}]}]}, {"title": "Fasting Plasma Glucose", "description": "Blood glucose was measured on a fasting basis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "138.4", "spread": "47.2"}, {"groupId": "BG001", "value": "138.6", "spread": "42.8"}, {"groupId": "BG002", "value": "134.6", "spread": "59.1"}, {"groupId": "BG003", "value": "142.2", "spread": "38.7"}, {"groupId": "BG004", "value": "138.6", "spread": "44.7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1C (A1C) at Week 20", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "1.58", "lowerLimit": "1.58"}, {"groupId": "OG001", "value": "-0.02", "spread": "1.45", "lowerLimit": "1.45"}, {"groupId": "OG002", "value": "-1.03", "spread": "0.72", "lowerLimit": "0.72"}, {"groupId": "OG003", "value": "0.57", "spread": "1.62", "lowerLimit": "1.62"}]}]}]}, {"type": "PRIMARY", "title": "Baseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm", "description": "A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had a baseline measurement of A1C.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo (Pooled)", "description": "Participants received placebo from Week 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.58", "spread": "1.06"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C from a longitudinal data analysis (LDA) model. The placebo arm in this comparison is a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The Statistical Analysis Plan (SAP) did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo (Pooled)", "description": "Participants received placebo from Week 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "lowerLimit": "-0.35", "upperLimit": "0.34"}, {"groupId": "OG001", "value": "0.18", "lowerLimit": "-0.17", "upperLimit": "0.53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.448", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The Least Squares (LS) Mean for the arm \"Sitagliptin\" is compared against that of \"Placebo (pooled)\".", "paramType": "Least Squares Means Difference", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.68", "ciUpperLimit": "0.30"}]}, {"type": "PRIMARY", "title": "Number of Participants Who Experienced \u22651 Adverse Event During Weeks 0-56", "description": "The number of participants experiencing \u22651 adverse event during Weeks 0-56 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 56", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "67"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "4"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced \u22651 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)", "description": "The number of participants experiencing \u22651 adverse event during Weeks 0-56 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication. Participants (n=5) from the Placebo/Sitagliptin arm were excluded because sitagliptin received during Week 0-54 was an inappropriate control for the Sitagliptin arm which received sitagliptin during both study treatment phases.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 56", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "76.8"}, {"groupId": "OG001", "value": "74.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValueComment": "Percentage of participants with \u22651 adverse event for the arm \"Sitagliptin\" was compared against that of \"Placebo/Metformin\" with Miettinen \\& Nurminen.", "paramType": "Difference in Percentage", "paramValue": "2.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.0", "ciUpperLimit": "14.9"}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54", "description": "The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)", "description": "The percentage of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication. Participants (n=5) from the Placebo/Sitagliptin arm were excluded because sitagliptin received during Week 0-54 was an inappropriate control for the Sitagliptin arm which received sitagliptin during both study treatment phases.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.3"}, {"groupId": "OG001", "value": "1.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValueComment": "Percentage of participants with \u22651 adverse event for the arm \"Sitagliptin\" was compared against that of \"Placebo/Metformin\" with Miettinen \\& Nurminen.", "paramType": "Difference in percentage", "paramValue": "4.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.3", "ciUpperLimit": "10.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C at Week 54", "description": "A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. This change from baseline reflects the Week 54 A1C minus the Week 0 A1C.", "populationDescription": "The analysis population included all randomized participants who took at least one dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.19", "spread": "1.37"}, {"groupId": "OG001", "value": "-0.90", "spread": "1.41"}, {"groupId": "OG002", "value": "-0.70", "spread": "0.94"}, {"groupId": "OG003", "value": "-0.50", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<7.0%) at Week 20", "description": "The percentage of participants with A1C at goal (\\<7.0%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "49.5"}, {"groupId": "OG001", "value": "37.8"}, {"groupId": "OG002", "value": "77.8"}, {"groupId": "OG003", "value": "20.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))", "description": "The percentage of participants with A1C at goal (\\<7.0%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo (Pooled)", "description": "Participants received placebo from Week 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "49.5"}, {"groupId": "OG001", "value": "36.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.374", "pValueComment": "Percentage of participants with an A1C goal (7.0%) in the arm \"Sitagliptin\" was compared against the arm \"Placebo (pooled)\".", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Difference in percentage", "paramValue": "6.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.1", "ciUpperLimit": "21.2", "otherAnalysisDescription": "For estimating the treatment difference, when the A1C result for a participant at Week 20 was not available, a multiple imputation method based on the Linear Discriminant Analysis (LDA) model was used to impute whether the participant had met the goal."}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<6.5%) at Week 20", "description": "The percentage of participants with A1C at goal (\\<6.5%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.5"}, {"groupId": "OG001", "value": "23.3"}, {"groupId": "OG002", "value": "66.7"}, {"groupId": "OG003", "value": "20.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<6.5%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))", "description": "The percentage of participants with A1C at goal (\\<6.5%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo (Pooled)", "description": "Participants received placebo from Week 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.5"}, {"groupId": "OG001", "value": "23.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.639", "statisticalMethod": "Miettinen and Nurminen", "statisticalComment": "The percentage of participants with an A1C at the A1C goal (6.5%) in the arm \"Sitagliptin\" was compared against the arm \"Placebo (pooled)\".", "paramType": "Difference in percentage", "paramValue": "3.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.6", "ciUpperLimit": "18.3", "otherAnalysisDescription": "For estimating the treatment difference, when the A1C result for a participant at Week 20 was not available, a multiple imputation method based on the LDA model was used to impute whether the participant had met the goal."}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<7.0%) at Week 54", "description": "The percentage of participants with A1C at goal (\\<7.0%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.4"}, {"groupId": "OG001", "value": "40.0"}, {"groupId": "OG002", "value": "33.3"}, {"groupId": "OG003", "value": "20.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<6.5%) at Week 54", "description": "The percentage of participants with A1C at goal (\\<6.5%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.0"}, {"groupId": "OG001", "value": "35.6"}, {"groupId": "OG002", "value": "22.2"}, {"groupId": "OG003", "value": "20.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20", "description": "Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.98", "spread": "61.86", "lowerLimit": "61.86"}, {"groupId": "OG001", "value": "7.59", "spread": "41.11", "lowerLimit": "41.11"}, {"groupId": "OG002", "value": "-19.88", "spread": "49.78", "lowerLimit": "49.78"}, {"groupId": "OG003", "value": "57.67", "spread": "51.05", "lowerLimit": "51.05"}]}]}]}, {"type": "SECONDARY", "title": "Baseline Fasting Plasma Glucose (FPG) for the Placebo (Pooled) Arm", "description": "Blood glucose was measured on a fasting basis. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo (Pooled)", "description": "Participants received placebo from Week 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "138.8", "spread": "42.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))", "description": "Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline and was estimated from a longitudinal data analysis model. The current outcome measure focused on results from participants randomized to sitagliptin or placebo. The Week 20 treatment comparison of Sitagliptin vs Placebo included all participants treated with Sitagliptin or Placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo (Pooled)", "description": "Participants received placebo from Week 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.2", "lowerLimit": "-4.2", "upperLimit": "18.7"}, {"groupId": "OG001", "value": "5.7", "lowerLimit": "-6.0", "upperLimit": "17.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.849", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The Least Squares (LS) Mean for the arm \"Sitagliptin\" was compared against that of \"Placebo (pooled)\".", "paramType": "Least Squares Means Difference", "paramValue": "1.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.4", "ciUpperLimit": "17.5"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 54", "description": "Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 54 minus FPG at baseline.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "51"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.03", "spread": "48.55"}, {"groupId": "OG001", "value": "-4.52", "spread": "50.68"}, {"groupId": "OG002", "value": "-29.92", "spread": "53.19"}, {"groupId": "OG003", "value": "3.00", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 20", "description": "PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour PMG minus the Week 0 2-hour PMG.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint both at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.9", "spread": "42.6", "lowerLimit": "42.6"}, {"groupId": "OG001", "value": "2.1", "spread": "72.1", "lowerLimit": "72.1"}, {"groupId": "OG002", "value": "-6.8", "spread": "21.1", "lowerLimit": "21.1"}, {"groupId": "OG003", "value": "63.5", "spread": "171.8", "lowerLimit": "171.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour PMG at Week 54", "description": "PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour PMG minus the Week 0 2-hour PMG.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint both at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "21.3"}, {"groupId": "OG001", "value": "-16.8", "spread": "48.9"}, {"groupId": "OG002", "value": "-39.7", "spread": "32.3"}, {"groupId": "OG003", "value": "-28.0", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour Incremental PMG at Week 20", "description": "2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint both at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "55.3", "lowerLimit": "55.3"}, {"groupId": "OG001", "value": "0.7", "spread": "35.9", "lowerLimit": "35.9"}, {"groupId": "OG002", "value": "0.8", "spread": "15.6", "lowerLimit": "15.6"}, {"groupId": "OG003", "value": "12.5", "spread": "98.3", "lowerLimit": "98.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Incremental PMG at Week 54", "description": "2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint both at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "64.6"}, {"groupId": "OG001", "value": "-26.6", "spread": "39.0"}, {"groupId": "OG002", "value": "-31.3", "spread": "34.8"}, {"groupId": "OG003", "value": "-32.0", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin at Week 20 for Participants Not on Background Insulin", "description": "This change from baseline reflects the Week 20 insulin minus the Week 0 insulin.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mIU/L", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.59", "spread": "47.24", "lowerLimit": "47.24"}, {"groupId": "OG001", "value": "-3.91", "spread": "22.31", "lowerLimit": "22.31"}, {"groupId": "OG002", "value": "-7.25", "spread": "60.58", "lowerLimit": "60.58"}, {"groupId": "OG003", "value": "-1.23", "spread": "20.55", "lowerLimit": "20.55"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin at Week 54 For Participants Not on Background Insulin", "description": "This change from baseline reflects the Week 54 insulin minus the Week 0 insulin.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mIU/L", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.65", "spread": "40.82"}, {"groupId": "OG001", "value": "-6.64", "spread": "32.01"}, {"groupId": "OG002", "value": "-20.50", "spread": "65.08"}, {"groupId": "OG003", "value": "-9.95", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Proinsulin at Week 20 For Participants Not on Background Insulin", "description": "This change from baseline reflects the Week 20 proinsulin minus the Week 0 proinsulin.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pmol/L", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "spread": "81.88", "lowerLimit": "81.88"}, {"groupId": "OG001", "value": "-10.88", "spread": "55.12", "lowerLimit": "55.12"}, {"groupId": "OG002", "value": "12.57", "spread": "36.98", "lowerLimit": "36.98"}, {"groupId": "OG003", "value": "-1.33", "spread": "9.07", "lowerLimit": "9.07"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Proinsulin at Week 54 For Participants Not on Background Insulin", "description": "This change from baseline reflects the Week 54 proinsulin minus the Week 0 proinsulin.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pmol/L", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.62", "spread": "67.54"}, {"groupId": "OG001", "value": "-16.13", "spread": "81.52"}, {"groupId": "OG002", "value": "-23.30", "spread": "42.36"}, {"groupId": "OG003", "value": "-0.50", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Proinsulin/Insulin Ratio at Week 20 for Participants Not on Background Insulin", "description": "Change from baseline was the Week 20 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "55"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.22", "lowerLimit": "0.22"}, {"groupId": "OG001", "value": "0.02", "spread": "0.16", "lowerLimit": "0.16"}, {"groupId": "OG002", "value": "-0.03", "spread": "0.10", "lowerLimit": "0.10"}, {"groupId": "OG003", "value": "-0.19", "spread": "0.45", "lowerLimit": "0.45"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Proinsulin/Insulin Ratio at Week 54 For Participants Not on Background Insulin", "description": "The change from baseline was Week 54 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.23"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.19"}, {"groupId": "OG002", "value": "-0.01", "spread": "0.06"}, {"groupId": "OG003", "value": "0.02", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Homeostatic Model Assessment of \u03b2-cell Function (HOMA-\u03b2) at Week 20 For Participants Not on Background Insulin", "description": "HOMA-\u03b2 = 20 \u00d7 fasting insulin (in mcIU/mL) \u00f7 {\\[FPG (in mg/dL)/18\\] - 3.5}. The change from baseline was Week 20 HOMA-\u03b2 minus the Week 0 HOMA-\u03b2.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of Beta Cell Function", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.72", "spread": "162.47", "lowerLimit": "162.47"}, {"groupId": "OG001", "value": "-53.23", "spread": "296.23", "lowerLimit": "296.23"}, {"groupId": "OG002", "value": "-1757.50", "spread": "4765.46", "lowerLimit": "4765.46"}, {"groupId": "OG003", "value": "-64.78", "spread": "126.65", "lowerLimit": "126.65"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in HOMA-\u03b2 at Week 54 For Participants Not on Background Insulin", "description": "HOMA-\u03b2 = 20 \u00d7 fasting insulin (in mcIU/mL) \u00f7 {\\[FPG (in mg/dL)/18\\] - 3.5}. This change from baseline was Week 54 HOMA-\u03b2 minus the Week 0 HOMA-\u03b2.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of Beta Cell Function", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-41.15", "spread": "183.17"}, {"groupId": "OG001", "value": "-63.88", "spread": "339.74"}, {"groupId": "OG002", "value": "-1860.69", "spread": "4099.22"}, {"groupId": "OG003", "value": "-121.48", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 20 For Participants Not on Background Insulin", "description": "HOMA-IR = fasting insulin (in mcIU/mL) \u00d7 FPG (in mg/dL) / (22.5\u00d718). This change from baseline was Week 20 HOMA-IR minus the Week 0 HOMA-IR.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Index of insulin resistance", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "31.62", "lowerLimit": "31.62"}, {"groupId": "OG001", "value": "-0.86", "spread": "9.02", "lowerLimit": "9.02"}, {"groupId": "OG002", "value": "-4.46", "spread": "34.65", "lowerLimit": "34.65"}, {"groupId": "OG003", "value": "2.58", "spread": "9.30", "lowerLimit": "9.30"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in HOMA-IR at Week 54 For Participants Not on Background Insulin", "description": "HOMA-IR = fasting insulin (in mcIU/mL) \u00d7 FPG (in mg/dL) / (22.5\u00d718). This change from baseline was Week 54 HOMA-IR minus the Week 0 HOMA-IR.", "populationDescription": "The analysis population included all randomized participants not on background insulin who received \u22651 dose of study medication and had data for the analysis endpoint both at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Index of insulin resistance", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.13", "spread": "34.86"}, {"groupId": "OG001", "value": "-1.30", "spread": "15.31"}, {"groupId": "OG002", "value": "-15.18", "spread": "36.41"}, {"groupId": "OG003", "value": "-2.21", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glucose 3-Hour Total Area Under the Curve (AUC) at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg*hr/dL", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-49.3", "spread": "103.6", "lowerLimit": "103.6"}, {"groupId": "OG001", "value": "2.0", "spread": "190.0", "lowerLimit": "190.0"}, {"groupId": "OG002", "value": "18.6", "spread": "50.9", "lowerLimit": "50.9"}, {"groupId": "OG003", "value": "191.0", "spread": "434.2", "lowerLimit": "434.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin 3-hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b5IU*hr/mL", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.5", "spread": "128.0", "lowerLimit": "128.0"}, {"groupId": "OG001", "value": "-32.8", "spread": "99.9", "lowerLimit": "99.9"}, {"groupId": "OG002", "value": "141.7", "spread": "206.1", "lowerLimit": "206.1"}, {"groupId": "OG003", "value": "-145.6", "spread": "180.6", "lowerLimit": "180.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in C-peptide 3-Hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "4.9", "lowerLimit": "4.9"}, {"groupId": "OG001", "value": "-0.1", "spread": "3.3", "lowerLimit": "3.3"}, {"groupId": "OG002", "value": "5.9", "spread": "7.6", "lowerLimit": "7.6"}, {"groupId": "OG003", "value": "-6.4", "spread": "7.1", "lowerLimit": "7.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin 3-Hour AUC/ Glucose 3-Hour AUC Ratio at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin total AUC/glucose total AUC ratio minus the Week 0 insulin total AUC/glucose total AUC ratio.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "[\u00b5IU*hr/mL]/[mg*hr/dL]", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.3", "lowerLimit": "0.3"}, {"groupId": "OG001", "value": "-0.1", "spread": "0.3", "lowerLimit": "0.3"}, {"groupId": "OG002", "value": "0.2", "spread": "0.4", "lowerLimit": "0.4"}, {"groupId": "OG003", "value": "-0.2", "spread": "0.3", "lowerLimit": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glucose Excursion 3-Hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg*hr/dL", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-43.5", "spread": "97.4", "lowerLimit": "97.4"}, {"groupId": "OG001", "value": "10.8", "spread": "58.6", "lowerLimit": "58.6"}, {"groupId": "OG002", "value": "39.8", "spread": "50.1", "lowerLimit": "50.1"}, {"groupId": "OG003", "value": "46.2", "spread": "201.9", "lowerLimit": "201.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin Excursion 3-Hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b5IU*hr/mL", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.4", "spread": "89.4", "lowerLimit": "89.4"}, {"groupId": "OG001", "value": "-19.4", "spread": "93.6", "lowerLimit": "93.6"}, {"groupId": "OG002", "value": "87.5", "spread": "124.5", "lowerLimit": "124.5"}, {"groupId": "OG003", "value": "-82.8", "spread": "93.4", "lowerLimit": "93.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in C-peptide Excursion 3-Hour AUC at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/ml", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "3.1", "lowerLimit": "3.1"}, {"groupId": "OG001", "value": "-0.4", "spread": "4.4", "lowerLimit": "4.4"}, {"groupId": "OG002", "value": "4.1", "spread": "5.6", "lowerLimit": "5.6"}, {"groupId": "OG003", "value": "-4.8", "spread": "5.2", "lowerLimit": "5.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 20", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "[\u03bcIU*hr/mL]/[mg*hr/dL]", "timeFrame": "Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "9.6", "lowerLimit": "9.6"}, {"groupId": "OG001", "value": "7.2", "spread": "17.5", "lowerLimit": "17.5"}, {"groupId": "OG002", "value": "-2.5", "spread": "3.2", "lowerLimit": "3.2"}, {"groupId": "OG003", "value": "1.4", "spread": "2.2", "lowerLimit": "2.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glucose 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg*hr/dL", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21.1", "spread": "47.7"}, {"groupId": "OG001", "value": "-36.0", "spread": "136.1"}, {"groupId": "OG002", "value": "-73.1", "spread": "95.8"}, {"groupId": "OG003", "value": "-63.3", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b5IU*hr/mL", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-43.2", "spread": "259.8"}, {"groupId": "OG001", "value": "-253.9", "spread": "282.7"}, {"groupId": "OG002", "value": "-37.8", "spread": "9.4"}, {"groupId": "OG003", "value": "-184.4", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in C-peptide 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/ml", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "5.7"}, {"groupId": "OG001", "value": "-6.1", "spread": "8.2"}, {"groupId": "OG002", "value": "1.7", "spread": "1.0"}, {"groupId": "OG003", "value": "-8.9", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin 3-Hour AUC/Glucose 3-Hour AUC Ratio at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC/glucose 3-hour AUC ratio minus the Week 0 insulin 3-hour AUC/glucose 3-hour AUC ratio.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "[\u03bcIU*hr/mL]/[mg*hr/dL]", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.5"}, {"groupId": "OG001", "value": "-0.6", "spread": "0.8"}, {"groupId": "OG002", "value": "-0.0", "spread": "0.2"}, {"groupId": "OG003", "value": "-0.3", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glucose Excursion 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg*hr/dL", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-30.7", "spread": "100.7"}, {"groupId": "OG001", "value": "-50.1", "spread": "79.5"}, {"groupId": "OG002", "value": "-49.0", "spread": "87.5"}, {"groupId": "OG003", "value": "-74.0", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin Excursion 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b5IU*hr/mL", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-103.8", "spread": "151.0"}, {"groupId": "OG001", "value": "-198.5", "spread": "263.0"}, {"groupId": "OG002", "value": "-40.2", "spread": "11.5"}, {"groupId": "OG003", "value": "-116.6", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in C-Peptide Excursion 3-Hour AUC at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/ml", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "3.0"}, {"groupId": "OG001", "value": "-5.2", "spread": "8.8"}, {"groupId": "OG002", "value": "0.9", "spread": "0.5"}, {"groupId": "OG003", "value": "-5.9", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 54", "description": "AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication, consented to participate in the MTT, and had data for the analysis endpoint at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "[\u00b5IU*hr/mL]/[mg*hr/dL]", "timeFrame": "Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.1", "spread": "13.1"}, {"groupId": "OG001", "value": "3.7", "spread": "5.6"}, {"groupId": "OG002", "value": "-2.7", "spread": "4.3"}, {"groupId": "OG003", "value": "1.4", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20", "description": "The percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.3"}, {"groupId": "OG001", "value": "11.1"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "40.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Initiating Glycemic Rescue Therapy by Week 54", "description": "The percentage of participants who initiated glycemic rescue therapy prior to Week 54 was reported.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35.8"}, {"groupId": "OG001", "value": "28.9"}, {"groupId": "OG002", "value": "11.1"}, {"groupId": "OG003", "value": "80.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Mass Index (BMI) at Week 20", "description": "This change from baseline was Week 20 BMI minus the Week 0 BMI.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg/m^2", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "82"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "2.2", "lowerLimit": "2.2"}, {"groupId": "OG001", "value": "-0.7", "spread": "1.9", "lowerLimit": "1.9"}, {"groupId": "OG002", "value": "-0.8", "spread": "1.4", "lowerLimit": "1.4"}, {"groupId": "OG003", "value": "-1.7", "spread": "2.8", "lowerLimit": "2.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in BMI at Week 54", "description": "This change from baseline was Week 54 BMI minus the Week 0 BMI.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg/m^2", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "2.9"}, {"groupId": "OG001", "value": "-1.0", "spread": "2.9"}, {"groupId": "OG002", "value": "-0.6", "spread": "1.3"}, {"groupId": "OG003", "value": "-0.3", "spread": "1.6"}]}]}]}, {"type": "SECONDARY", "title": "Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 20", "description": "The percent change from baseline in CD26 = (\\[CD26 value at Week 20\\] - \\[baseline CD26 value\\]) \u00f7 baseline CD26 value \u00d7 100.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.06", "spread": "19.25", "lowerLimit": "19.25"}, {"groupId": "OG001", "value": "-1.78", "spread": "17.18", "lowerLimit": "17.18"}, {"groupId": "OG002", "value": "4.89", "spread": "1.90", "lowerLimit": "1.90"}, {"groupId": "OG003", "value": "14.57", "spread": "15.46", "lowerLimit": "15.46"}]}]}]}, {"type": "SECONDARY", "title": "Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 54", "description": "The percent change from baseline in CD26 = (\\[CD26 value at Week 54\\] - \\[baseline CD26 value\\]) \u00f7 baseline CD26 value \u00d7 100.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "55"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.74", "spread": "17.18"}, {"groupId": "OG001", "value": "4.27", "spread": "18.24"}, {"groupId": "OG002", "value": "12.63", "spread": "13.02"}, {"groupId": "OG003", "value": "-5.30", "spread": "4.19"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Calcitonin at Week 20 - Females", "description": "Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "46"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.5", "lowerLimit": "0.5"}, {"groupId": "OG001", "value": "-2.0", "spread": "11.7", "lowerLimit": "11.7"}, {"groupId": "OG002", "value": "0.0", "spread": "0.0", "lowerLimit": "0.0"}, {"groupId": "OG003", "value": "0.0", "spread": "0.0", "lowerLimit": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Calcitonin at Week 54 - Females", "description": "Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "43"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "0.6"}, {"groupId": "OG001", "value": "-1.9", "spread": "12.1"}, {"groupId": "OG002", "value": "0.0", "spread": "0.0"}, {"groupId": "OG003", "value": "0.3", "spread": "0.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Calcitonin at Week 20 - Males", "description": "Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "1.4", "lowerLimit": "1.4"}, {"groupId": "OG001", "value": "-0.2", "spread": "0.6", "lowerLimit": "0.6"}, {"groupId": "OG002", "value": "-1.6", "spread": "2.2", "lowerLimit": "2.2"}, {"groupId": "OG003", "value": "0.5", "spread": "0.6", "lowerLimit": "0.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Calcitonin at Week 54 - Males", "description": "Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "1.1"}, {"groupId": "OG001", "value": "-0.3", "spread": "0.9"}, {"groupId": "OG002", "value": "0.0", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "1.4", "spread": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Bone Collagen [u-NTx]/Creatinine Ratio at Week 20 - Females", "description": "Urine N-terminal cross-linking telopeptide of bone collagen \\[u-NTx\\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nmol(BCE)/mmol(creatinine)", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-28.7", "spread": "120.9", "lowerLimit": "120.9"}, {"groupId": "OG001", "value": "-41.2", "spread": "148.9", "lowerLimit": "148.9"}, {"groupId": "OG002", "value": "-98.0", "spread": "153.0", "lowerLimit": "153.0"}, {"groupId": "OG003", "value": "12.7", "spread": "29.2", "lowerLimit": "29.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline u-NTx/Creatinine Ratio at Week 20 - Males", "description": "Urine N-terminal cross-linking telopeptide of bone collagen \\[u-NTx\\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nmol(BCE)/mmol(creatinine)", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-30.9", "spread": "167.2"}, {"groupId": "OG001", "value": "-69.8", "spread": "162.1"}, {"groupId": "OG002", "value": "62.0", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "-29.0", "spread": "32.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Females", "description": "Urine N-terminal cross-linking telopeptide of bone collagen \\[u-NTx\\]/creatinine ratio is a biochemical marker of bone turnover/resorption. Bone Collagen Equivalents", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nmol(BCE)/mmol(creatinine)", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-88.4", "spread": "102.6"}, {"groupId": "OG001", "value": "-61.2", "spread": "137.6"}, {"groupId": "OG002", "value": "-80.3", "spread": "208.5"}, {"groupId": "OG003", "value": "-17.0", "spread": "13.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Males", "description": "Urine N-terminal cross-linking telopeptide of bone collagen \\[u-NTx\\]/creatinine ratio is a biochemical marker of bone turnover/resorption. All participants in the Metformin arm were missing baseline or Week 54 measurements. BCE = Bone Collagen Equivalents", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nmol(BCE)/mmol(creatinine)", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-78.2", "spread": "166.9"}, {"groupId": "OG001", "value": "-102.4", "spread": "267.7"}, {"groupId": "OG003", "value": "-30.0", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Females", "description": "Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg/L", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.0", "spread": "13.7", "lowerLimit": "13.7"}, {"groupId": "OG001", "value": "-4.2", "spread": "9.9", "lowerLimit": "9.9"}, {"groupId": "OG002", "value": "-9.7", "spread": "7.7", "lowerLimit": "7.7"}, {"groupId": "OG003", "value": "10.7", "spread": "9.7", "lowerLimit": "9.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Females", "description": "Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg/L", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "43"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.0", "spread": "28.4"}, {"groupId": "OG001", "value": "-13.5", "spread": "18.1"}, {"groupId": "OG002", "value": "-14.9", "spread": "10.3"}, {"groupId": "OG003", "value": "-6.9", "spread": "9.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Males", "description": "Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg/L", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.2", "spread": "21.6", "lowerLimit": "21.6"}, {"groupId": "OG001", "value": "0.1", "spread": "19.9", "lowerLimit": "19.9"}, {"groupId": "OG002", "value": "-7.1", "spread": "0.2", "lowerLimit": "0.2"}, {"groupId": "OG003", "value": "4.7", "spread": "8.2", "lowerLimit": "8.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Males", "description": "Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg/L", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.2", "spread": "28.0"}, {"groupId": "OG001", "value": "-15.0", "spread": "27.0"}, {"groupId": "OG002", "value": "-1.3", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "-15.3", "spread": "12.4"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) at Week 20 - Females", "description": "IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\\[IGF-1 value at Week 20\\] - \\[baseline IGF-1 value\\]) \u00f7 \\[baseline IGF-1 value\\] \u00d7 100.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "21.9", "lowerLimit": "21.9"}, {"groupId": "OG001", "value": "11.0", "spread": "34.0", "lowerLimit": "34.0"}, {"groupId": "OG002", "value": "-3.2", "spread": "14.9", "lowerLimit": "14.9"}, {"groupId": "OG003", "value": "41.4", "spread": "31.2", "lowerLimit": "31.2"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in IGF-1 at Week 54 - Females", "description": "IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\\[IGF-1 value at Week 54\\] - \\[baseline IGF-1 value\\]) \u00f7 \\[baseline IGF-1 value\\] \u00d7 100.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "34.4"}, {"groupId": "OG001", "value": "7.2", "spread": "57.6"}, {"groupId": "OG002", "value": "-11.9", "spread": "13.4"}, {"groupId": "OG003", "value": "-13.5", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in IGF-1 at Week 20 - Males", "description": "IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\\[IGF-1 value at Week 20\\] - \\[baseline IGF-1 value\\]) \u00f7 \\[baseline IGF-1 value\\] \u00d7 100.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "spread": "22.1", "lowerLimit": "22.1"}, {"groupId": "OG001", "value": "9.3", "spread": "29.6", "lowerLimit": "29.6"}, {"groupId": "OG002", "value": "7.6", "spread": "17.4", "lowerLimit": "17.4"}, {"groupId": "OG003", "value": "5.3", "spread": "16.2", "lowerLimit": "16.2"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in IGF-1 at Week 54 - Males", "description": "IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\\[IGF-1 value at Week 54\\] - \\[baseline IGF-1 value\\]) \u00f7 \\[baseline IGF-1 value\\] \u00d7 100.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.9", "spread": "33.5"}, {"groupId": "OG001", "value": "29.6", "spread": "99.8"}, {"groupId": "OG002", "value": "18.8", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "-6.8", "spread": "22.1"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) at Week 20 - Females", "description": "IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\\[IGF-BP3 value at Week 20\\] - \\[baseline IGF-BP3 value\\]) \u00f7 \\[baseline IGF-BP3 value\\] \u00d7 100.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.5", "spread": "18.2", "lowerLimit": "18.2"}, {"groupId": "OG001", "value": "3.8", "spread": "13.8", "lowerLimit": "13.8"}, {"groupId": "OG002", "value": "8.4", "spread": "12.9", "lowerLimit": "12.9"}, {"groupId": "OG003", "value": "-0.7", "spread": "24.1", "lowerLimit": "24.1"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in IGF-BP3 at Week 54 - Females", "description": "IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\\[IGF-BP3 value at Week 54\\] - \\[baseline IGF-BP3 value\\]) \u00f7 \\[baseline IGF-BP3 value\\] \u00d7 100.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "16.7"}, {"groupId": "OG001", "value": "4.5", "spread": "17.0"}, {"groupId": "OG002", "value": "11.4", "spread": "17.4"}, {"groupId": "OG003", "value": "-13.4", "spread": "9.9"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in IGF-BP3 at Week 20 - Males", "description": "IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\\[IGF-BP3 value at Week 20\\] - \\[baseline IGF-BP3 value\\]) \u00f7 \\[baseline IGF-BP3 value\\] \u00d7 100.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.6", "spread": "13.3", "lowerLimit": "13.3"}, {"groupId": "OG001", "value": "10.2", "spread": "18.6", "lowerLimit": "18.6"}, {"groupId": "OG002", "value": "3.3", "spread": "0.5", "lowerLimit": "0.5"}, {"groupId": "OG003", "value": "14.2", "spread": "50.6", "lowerLimit": "50.6"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in IGF-BP3 at Week 54 - Males", "description": "IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\\[IGF-BP3 value at Week 54\\] - \\[baseline IGF-BP3 value\\]) \u00f7 \\[baseline IGF-BP3 value\\] \u00d7 100.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.4", "spread": "18.4"}, {"groupId": "OG001", "value": "18.2", "spread": "43.1"}, {"groupId": "OG002", "value": "-2.9", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "22.5", "spread": "8.3"}]}]}]}, {"type": "SECONDARY", "title": "Growth Velocity at Week 20 - Females", "description": "Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had height data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm/year", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "53"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "8.2", "lowerLimit": "8.2"}, {"groupId": "OG001", "value": "1.9", "spread": "2.7", "lowerLimit": "2.7"}, {"groupId": "OG002", "value": "5.0", "spread": "6.8", "lowerLimit": "6.8"}, {"groupId": "OG003", "value": "0.6", "spread": "1.6", "lowerLimit": "1.6"}]}]}]}, {"type": "SECONDARY", "title": "Growth Velocity at Week 54 - Females", "description": "Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had height data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm/year", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "3.7"}, {"groupId": "OG001", "value": "1.2", "spread": "1.8"}, {"groupId": "OG002", "value": "2.4", "spread": "2.9"}, {"groupId": "OG003", "value": "0.7", "spread": "1.0"}]}]}]}, {"type": "SECONDARY", "title": "Growth Velocity at Week 20 - Males", "description": "Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had height data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm/year", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.6", "spread": "2.7", "lowerLimit": "2.7"}, {"groupId": "OG001", "value": "3.6", "spread": "3.2", "lowerLimit": "3.2"}, {"groupId": "OG002", "value": "-1.0", "spread": "1.3", "lowerLimit": "1.3"}, {"groupId": "OG003", "value": "1.7", "spread": "2.4", "lowerLimit": "2.4"}]}]}]}, {"type": "SECONDARY", "title": "Growth Velocity at Week 54 - Males", "description": "Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had height data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm/year", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "2.5"}, {"groupId": "OG001", "value": "2.8", "spread": "2.1"}, {"groupId": "OG002", "value": "1.7", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "2.8", "spread": "4.0"}]}]}]}, {"type": "SECONDARY", "title": "Skeletal Maturation at Week 20 - Females", "description": "Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from an X-ray of left hand and wrist.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had bone age data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "1.9", "lowerLimit": "1.9"}, {"groupId": "OG001", "value": "0.4", "spread": "1.8", "lowerLimit": "1.8"}, {"groupId": "OG002", "value": "1.7", "spread": "2.3", "lowerLimit": "2.3"}, {"groupId": "OG003", "value": "-0.8", "spread": "5.5", "lowerLimit": "5.5"}]}]}]}, {"type": "SECONDARY", "title": "Skeletal Maturation at Week 54 - Females", "description": "Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Placebo/Sitagliptin arm were missing baseline or Week 54 measurements.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had bone age data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "1.1"}, {"groupId": "OG001", "value": "1.0", "spread": "0.6"}, {"groupId": "OG002", "value": "1.3", "spread": "2.2"}]}]}]}, {"type": "SECONDARY", "title": "Skeletal Maturation at Week 20 - Males", "description": "Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had bone age data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.6", "spread": "1.7"}, {"groupId": "OG001", "value": "1.2", "spread": "1.1"}, {"groupId": "OG002", "value": "0.4", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "2.4", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Skeletal Maturation at Week 54 - Males", "description": "Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Metformin and Placebo/Sitagliptin arms were missing baseline or Week 54 measurements.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had bone age data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "0.9"}, {"groupId": "OG001", "value": "1.3", "spread": "0.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Tanner Staging for Genitalia at Week 20 - Males", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 20 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "0.5"}, {"groupId": "OG001", "value": "0.2", "spread": "0.4"}, {"groupId": "OG002", "value": "0.0", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "0.5", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Tanner Staging for Genitalia at Week 54 - Males", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 54 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia. All participants in the Metformin arm were missing baseline or Week 54 measurements.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "0.6"}, {"groupId": "OG001", "value": "0.6", "spread": "0.7"}, {"groupId": "OG003", "value": "0.6", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Tanner Staging for Breasts at Week 20 - Females", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 20 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a Scale", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "0.6", "lowerLimit": "0.6"}, {"groupId": "OG001", "value": "0.1", "spread": "0.3", "lowerLimit": "0.3"}, {"groupId": "OG002", "value": "0.2", "spread": "0.4", "lowerLimit": "0.4"}, {"groupId": "OG003", "value": "0.3", "spread": "0.6", "lowerLimit": "0.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Tanner Staging for Breasts at Week 54 - Females", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 54 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a Scale", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "0.7"}, {"groupId": "OG001", "value": "0.4", "spread": "0.6"}, {"groupId": "OG002", "value": "0.5", "spread": "1.0"}, {"groupId": "OG003", "value": "0.7", "spread": "0.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Females", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "43"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "0.4", "lowerLimit": "0.4"}, {"groupId": "OG001", "value": "0.1", "spread": "0.3", "lowerLimit": "0.3"}, {"groupId": "OG002", "value": "0.2", "spread": "0.4", "lowerLimit": "0.4"}, {"groupId": "OG003", "value": "0.0", "spread": "0.0", "lowerLimit": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Females", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.", "populationDescription": "The analysis population included all female randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "0.6"}, {"groupId": "OG001", "value": "0.3", "spread": "0.5"}, {"groupId": "OG002", "value": "0.8", "spread": "1.5"}, {"groupId": "OG003", "value": "0.3", "spread": "0.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Males", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "0.5"}, {"groupId": "OG001", "value": "0.2", "spread": "0.4"}, {"groupId": "OG002", "value": "0.0", "spread": "NA", "comment": "\"NA\" The standard deviation could not be calculated because only one participant was analyzed."}, {"groupId": "OG003", "value": "0.5", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Males", "description": "Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.", "populationDescription": "The analysis population included all male randomized participants who received \u22651 dose of study medication and had data for the analysis endpoint at both baseline and Week 54. Tanner staging results for pubic hair were unavailable for the Metformin arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "0.7"}, {"groupId": "OG001", "value": "0.6", "spread": "0.5"}, {"groupId": "OG003", "value": "0.5", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Worsening in Dental Status at Week 20", "description": "Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 20 dental assessments versus baseline dental assessments.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had dental data at baseline and Week 20.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"title": "1. With \u22651 tooth with worsening in any category", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "2. With \u22651 tooth with worsening fracture", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "3. With \u22651 tooth with worsening discoloration", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "4. With \u22651 tooth with worsening enamel defect", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Worsening in Dental Status at Week 54", "description": "Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 54 dental assessments versus baseline dental assessments.", "populationDescription": "The analysis population included all randomized participants who received \u22651 dose of study medication and had dental data at baseline and Week 54.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}, {"id": "OG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"title": "1. With \u22651 tooth with worsening in any category", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "2. With \u22651 tooth with worsening fracture", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "3. With \u22651 tooth with worsening discoloration", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "4. With \u22651 with worsening enamel defect", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "SAEs and AEs: Up to approximately Week 56. Deaths: Up to approximately 42 months after randomization.", "description": "The All-Cause Mortality analysis population consisted of all randomized participants. The AE analysis population consisted of all participants who received \u22651 dose of study medication and included all post-randomization follow-ups. One participant in the Sitagliptin arm died after the treatment phases of the study, approximately 42 months after randomization.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.", "deathsNumAffected": 1, "deathsNumAtRisk": 96, "seriousNumAffected": 10, "seriousNumAtRisk": 95, "otherNumAffected": 62, "otherNumAtRisk": 95}, {"id": "EG001", "title": "Placebo/Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.", "deathsNumAffected": 0, "deathsNumAtRisk": 90, "seriousNumAffected": 7, "seriousNumAtRisk": 90, "otherNumAffected": 53, "otherNumAtRisk": 90}, {"id": "EG002", "title": "Metformin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants continued to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 1, "seriousNumAtRisk": 9, "otherNumAffected": 7, "otherNumAtRisk": 9}, {"id": "EG003", "title": "Placebo/Sitagliptin", "description": "Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.", "deathsNumAffected": 0, "deathsNumAtRisk": 5, "seriousNumAffected": 3, "seriousNumAtRisk": 5, "otherNumAffected": 4, "otherNumAtRisk": 5}], "seriousEvents": [{"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Abscess soft tissue", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Dengue fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Acute lymphocytic leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Affect lability", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Ovarian cyst ruptured", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Erythema nodosum", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Sexual abuse", "organSystem": "Social circumstances", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}], "otherEvents": [{"term": "Wandering pacemaker", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Blepharitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Eye pain", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 8, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 10, "numAffected": 7, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 8, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 14, "numAffected": 11, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 3, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 6, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 4, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 10, "numAffected": 7, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 15, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Pertussis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 12, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 13, "numAffected": 12, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 11, "numAffected": 9, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 4, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Tooth fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 107, "numAffected": 16, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 37, "numAffected": 12, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 65, "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 5}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 4, "numAffected": 2, "numAtRisk": 5}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 16, "numAffected": 13, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 5, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Gynaecomastia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Hyperventilation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Respiratory disorder", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 95}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme LLC", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-06-12", "uploadDate": "2020-10-05T10:22", "filename": "Prot_SAP_000.pdf", "size": 2273858}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Australia", "Austria", "Brazil", "Bulgaria", "Canada", "Chile", "China", "Colombia", "Costa Rica", "Denmark", "Dominican Republic", "France", "Georgia", "Germany", "Greece", "Guatemala", "Honduras", "Hungary", "Israel", "Italy", "Latvia", "Lithuania", "Malaysia", "Mauritius", "Mexico", "Moldova, Republic of", "New Zealand", "Panama", "Philippines", "Poland", "Romania", "Russian Federation", "Saudi Arabia", "Serbia", "Slovakia", "South Africa", "Spain", "Sweden", "Thailand", "United Arab Emirates", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}